Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
56 studies found for:    Northwestern AND Pulmonary hypertension
Show Display Options
Rank Status Study
1 Completed
Has Results
Ranolazine and Pulmonary Hypertension
Conditions: Angina;   Pulmonary Arterial Hypertension
Intervention: Drug: Ranolazine
2 Completed Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery
Conditions: Pulmonary Hypertension;   Mitral Valve Disease
Intervention:
3 Completed
Has Results
Incidence of Obstructive Sleep Apnea in Pregnancy
Conditions: Obstructive Sleep Apnea;   Pregnancy
Intervention: Procedure: Survey: Berlin questionnaire
4 Unknown  A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil), 2 FDA Approved Pulmonary Hypertension Medications
Condition: Hypertension, Pulmonary
Interventions: Drug: inhaled treprostinil;   Drug: tadalafil
5 Unknown  Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Conditions: Sarcoidosis;   Pulmonary Hypertension
Intervention: Drug: Ambrisentan
6 Completed Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Conditions: Systemic Sclerosis;   Scleroderma;   Pulmonary Hypertension;   Pulmonary Arterial Hypertension
Intervention:
7 Terminated Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension
Conditions: Persistent Pulmonary Hypertension;   Respiratory Failure
Interventions: Drug: Intravenous Sildenafil;   Other: Placebo
8 Terminated
Has Results
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
Conditions: Chronic Obstructive Pulmonary Disease;   Pulmonary Hypertension
Interventions: Drug: Iloprost;   Drug: Placebo
9 Recruiting Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Condition: Pulmonary Hypertension
Intervention: Drug: Bardoxolone methyl
10 Enrolling by invitation An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Conditions: Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
Intervention: Drug: Inhaled Treprostinil
11 Recruiting Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Conditions: Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
Interventions: Drug: Inhaled Treprostinil;   Drug: Placebo
12 Completed
Has Results
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention: Drug: Ambrisentan
13 Terminated
Has Results
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
Conditions: Heart Failure;   Pulmonary Hypertension
Interventions: Drug: Tadalafil;   Drug: Placebo for tadalafil
14 Terminated Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
Conditions: Systemic Sclerosis;   Pulmonary Arterial Hypertension;   Pulmonary Hypertension
Intervention:
15 Completed Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Condition: Bronchopulmonary Dysplasia
Interventions: Drug: Inhaled Nitric Oxide (iNO);   Drug: Nitrogen (placebo)
16 Withdrawn FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: UT-15C 1 mg;   Drug: UT-15C 0.25 mg;   Drug: UT-15C 5 mg;   Drug: Placebo
17 Completed
Has Results
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
Condition: Pulmonary Hypertension
Interventions: Drug: UT-15C SR;   Drug: Placebo
18 Completed
Has Results
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets;   Drug: Placebo
19 Completed
Has Results
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets;   Other: Placebo
20 Active, not recruiting Beraprost-314d Added-on to Tyvaso® (BEAT)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Beraprost Sodium 314d Modified Release Tablets;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.